US › Healthcare

Capricor Therapeutics Inc (CAPR)

US · Healthcare · Biotechnology

$4.17-0.71%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-33.9M
Profit YoY
-39.2%
EPS
$-0.59
EPS estimate
$-0.48

EPS came in at -0.59 against a street estimate of -0.48 — a miss of 23.4%.

Key statistics

Market cap
$223.0M
Forward P/E
78.7
P/B
0.80
Book value
$4.83
EPS (TTM)
$-2.32
52-week high
$40.37
52-week low
$2.96
50-day MA
$23.14
200-day MA
$23.28
Beta
0.42

Analyst view

Analysts rate Capricor Therapeutics Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $4.38.

Shareholding

Insiders
9.47%
Institutions
59.63%

Largest institutional holders

FundStake
Suvretta Capital Management, LLC6.59%
BlackRock Inc5.91%
TANG CAPITAL MANAGEMENT LLC5.87%
State Street Corp3.77%
Vanguard Capital Management, LLC3.50%
RA Capital Management, LLC2.60%
Geode Capital Management, LLC1.93%
The Goldman Sachs Group Inc1.57%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Capricor Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.